At a Glance
- Company: GSK
- Partner: Engitix
- Funding: £44 million
- Focus area: Liver disease and fibrosis regression
- Next steps: Advance multiple discovery targets
What happened?
GSK has committed £44 million to UK biotech Engitix as part of a multi-target collaboration focused on liver disease and fibrosis regression. The deal gives Engitix support to advance its platform and associated programmes.
Why does it matter?
Fibrosis is a major unmet need across liver disease, and effective regression of scar tissue remains a difficult therapeutic goal. A multi-target approach could improve the odds of finding medicines that can both slow disease progression and potentially reverse damage.
Who’s behind it?
GSK is a global pharmaceutical company with a broad focus on respiratory, immunology, oncology and infectious disease. Engitix is a UK biotech working on extracellular matrix biology and fibrosis-related targets.
How was it achieved?
The collaboration is structured around multiple targets rather than a single asset, which can spread scientific risk across a broader discovery programme. GSK’s funding should help Engitix expand research efforts and progress candidate selection.
What’s next?
The partners will now work through target validation, hit discovery and programme advancement. If the collaboration is productive, it could feed future clinical candidates into GSK’s liver disease pipeline.